State Street Corp raised its holdings in Cryolife Inc (NYSE:CRY) by 5.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 758,840 shares of the medical equipment provider’s stock after purchasing an additional 37,279 shares during the period. State Street Corp owned 2.27% of Cryolife worth $15,143,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of CRY. Teachers Advisors LLC increased its position in Cryolife by 2.6% during the 1st quarter. Teachers Advisors LLC now owns 53,065 shares of the medical equipment provider’s stock valued at $884,000 after purchasing an additional 1,345 shares during the period. Legal & General Group Plc grew its position in Cryolife by 2.3% during the 1st quarter. Legal & General Group Plc now owns 46,175 shares of the medical equipment provider’s stock valued at $767,000 after purchasing an additional 1,022 shares during the last quarter. Thrivent Financial For Lutherans lifted its stake in Cryolife by 4.8% during the 1st quarter. Thrivent Financial For Lutherans now owns 15,200 shares of the medical equipment provider’s stock valued at $253,000 after acquiring an additional 700 shares during the period. Vanguard Group Inc. lifted its stake in Cryolife by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 1,556,106 shares of the medical equipment provider’s stock valued at $25,909,000 after acquiring an additional 43,212 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Cryolife by 2.9% during the 1st quarter. Geode Capital Management LLC now owns 207,318 shares of the medical equipment provider’s stock valued at $3,451,000 after acquiring an additional 5,931 shares during the period. Hedge funds and other institutional investors own 73.31% of the company’s stock.
Cryolife Inc (NYSE CRY) traded up $0.15 on Thursday, reaching $19.05. The company’s stock had a trading volume of 103,490 shares, compared to its average volume of 160,616. Cryolife Inc has a 52 week low of $14.02 and a 52 week high of $24.00. The stock has a market capitalization of $688.47, a price-to-earnings ratio of 45.98 and a beta of 0.82. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.96 and a quick ratio of 4.90.
Cryolife (NYSE:CRY) last issued its earnings results on Monday, October 30th. The medical equipment provider reported $0.08 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.08. Cryolife had a return on equity of 6.43% and a net margin of 5.28%. The firm had revenue of $44.00 million for the quarter, compared to analyst estimates of $44.60 million. During the same quarter in the prior year, the firm earned $0.13 earnings per share. Cryolife’s revenue for the quarter was down 2.9% on a year-over-year basis. research analysts predict that Cryolife Inc will post 0.28 earnings per share for the current fiscal year.
CRY has been the topic of several recent research reports. Canaccord Genuity reiterated a “buy” rating and issued a $25.00 price objective on shares of Cryolife in a research note on Monday, October 9th. Zacks Investment Research lowered shares of Cryolife from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Lake Street Capital raised their target price on shares of Cryolife to $26.00 and gave the company a “buy” rating in a report on Wednesday, October 11th. Northland Securities restated a “buy” rating and issued a $23.50 price target on shares of Cryolife in a research report on Monday, November 13th. Finally, TheStreet downgraded Cryolife from a “b” rating to a “c+” rating in a research report on Monday, October 30th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Cryolife currently has an average rating of “Hold” and an average target price of $23.63.
In other Cryolife news, CFO David Ashley Lee sold 33,190 shares of the company’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total value of $630,610.00. Following the completion of the sale, the chief financial officer now directly owns 324,339 shares in the company, valued at approximately $6,162,441. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director James Benson sold 2,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $22.80, for a total value of $45,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 60,190 shares of company stock valued at $1,163,840. Corporate insiders own 6.00% of the company’s stock.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for Cryolife Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife Inc and related companies with MarketBeat.com's FREE daily email newsletter.